Universidad CEU Cardenal Herrera-ko ikertzaileekin lankidetzan egindako argitalpenak (31)

2024

  1. Dual Antitubercular and Antileishmanial Profiles of Quinoxaline Di-N-Oxides Containing an Amino Acidic Side Chain

    Pharmaceuticals, Vol. 17, Núm. 4

2023

  1. Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers

    International journal of pharmaceutics, Vol. 635, pp. 122788

2020

  1. (E)-piplartine isolated from piper pseudoarboreum, a lead compound against leishmaniasis

    Foods, Vol. 9, Núm. 9

  2. Evaluating the potential of ursolic acid as bioproduct for cutaneous and visceral leishmaniasis

    Molecules, Vol. 25, Núm. 6

  3. Nucleotides and AHCC Enhance Th1 Responses in Vitro in Leishmania-Stimulated/Infected Murine Cells

    Molecules, Vol. 25, Núm. 17

  4. Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis

    International Journal of Pharmaceutics, Vol. 588

  5. Ultradeformable Lipid Vesicles Localize Amphotericin B in the Dermis for the Treatment of Infectious Skin Diseases

    ACS Infectious Diseases, Vol. 6, Núm. 10, pp. 2647-2660

2018

  1. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species

    Experimental Parasitology, Vol. 184, pp. 82-89

  2. Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 124, pp. 13-27

  3. Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis

    Molecular Pharmaceutics, Vol. 15, Núm. 7, pp. 2570-2583

  4. Systematic search for benzimidazole compounds and derivatives with antileishmanial effects

    Molecular Diversity, Vol. 22, Núm. 4, pp. 779-790

2017

  1. Engineering oral and parenteral amorphous amphotericin B formulations against experimental Trypanosoma cruzi infections

    Molecular Pharmaceutics, Vol. 14, Núm. 4, pp. 1095-1106

  2. Leishmaniasis in the major endemic region of Plurinational State of Bolivia: Species identification, phylogeography and drug susceptibility implications

    Acta Tropica, Vol. 176, pp. 150-161

2016

  1. Synthesis and antileishmanial activity of C7-and C12-functionalized dehydroabietylamine derivatives

    European Journal of Medicinal Chemistry, Vol. 121, pp. 445-450

2015

  1. Immunoproteomic analysis of Trichinella spiralis larval crude antigens recognized by sera from patients with trichinellosis after treatment with albendazole

    Tropical Biomedicine, Vol. 32, Núm. 4, pp. 613-624

  2. Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles

    Molecular Pharmaceutics, Vol. 12, Núm. 2, pp. 420-431

2014

  1. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp

    International Journal of Pharmaceutics, Vol. 473, Núm. 1-2, pp. 148-157

2013

  1. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations

    International Journal of Pharmaceutics, Vol. 447, Núm. 1-2, pp. 38-46

  2. Identification of proteins interacting with HSP70 mRNAs in Leishmania Braziliensis

    Journal of Proteomics, Vol. 94, pp. 124-137

  3. In vitro and in vivo antileishmanial and trypanocidal studies of new N -benzene- and N -naphthalenesulfonamide derivatives

    Journal of Medicinal Chemistry, Vol. 56, Núm. 22, pp. 8984-8998